Unlocked Labs Inc.

Unlocked Labs focuses on developing innovative probiotic supplements aimed at improving health by managing metabolic waste, with a unique emphasis on their lead product, Strain OX164, which targets oxalic acid breakdown. Founded in 2018 in San Francisco, US, Unlocked Labs specializes in probiotics. The company was established by Christoph Geisler, who has prior experience in launching other ventures. Unlocked Labs conducted its most recent funding round in April 2024, Unlocked Labs raised an undisclosed amount of venture funding from new investor Seaside Ventures.

Unlocked Probiotics specializes in next-generation probiotic supplements, focusing on their flagship product, Strain OX164. This probiotic is engineered to break down oxalic acid, supporting kidney health. Currently undergoing testing, these products are designed for daily use and aim to attract health-conscious consumers in North America and Europe once available for purchase. Unlocked Probiotics is set to operate on a direct-to-consumer model, providing Strain OX164 in single-dose sachets.

Their revenue structure will include subscription options for regular customers. While specific pricing details are not disclosed, the straightforward purchasing process via their website will facilitate customer retention and engagement. The company is also exploring additional targeted probiotics to diversify its revenue streams. Unlocked Labs is strategically positioning itself for growth by targeting the launch of Strain OX164 in health markets across North America and Europe.

The funding raised in December 2021 will aid in product development and market expansion efforts. Upcoming products are being designed to enhance their existing line and meet consumer demands, with plans for rollouts aligned with market readiness to ensure effective entry.